FEVER THERAPY IL2 & LONG-TERM HYPHERTHERMIA
Fever therapy with long-term hyperthermia
Long-term whole-body hyperthermia is induced by Heckel-HT 2000 , a device developed in Germany for applying heat. Your temperature is raised to a temperature level of 39.0 – 39.5 C °. Some patients are lightly sedated (sleeping / anesthetics) during hyperthermia in order to make the treatment as pleasant as possible. In very rare cases, sedation may make ventilation necessary. During hyperthermia, electrolyte and salt solutions are continuously given into a vein (iv). The amount of fluid administered to the patient and the amount of excretion (urine) are monitored and recorded.
Fever therapy with IL-2 (interleukin 2)
IL-2 was discovered by Steven Rosenberg’s group at the NCI (National Cancer Institute) at the NIH in Washington in the 1980s. The substance is approved worldwide for the treatment of kidney cancer and black skin cancer. These treatment protocols each provide for 1 week high-dose therapy with IL-2. Studies have shown that this therapy was able to bring about 6% of metastatic patients into remission in melanoma and up to 15% in kidney cancer.
The classic IL-2 high-dose therapy, however, has a number of sometimes dangerous side effects, in particular the so-called “vasculary leak syndrome”, a side effect that often even requires admission to an intensive care unit.
An Irish working group led by Prof. Redmond from the University Hospital in Cork / Ireland was able to show that the parallel administration of an amino acid called taurolidine drastically reduced the side effects of high-dose IL-2. Further anti-cancer mechanisms of Taurolidine are a reduction of proinflammatory cytokines, induction of apoptosis (programmed cell death), and antiangiogenic effects (inhibition of the formation of new intratumoral blood vessels).
Another known side effect of IL-2 is the occurrence of fever. We have therefore decided, often following therapy with checkpoint inhibitors, chemotherapy or radiation therapy, deliberately to use low doses of IL-2 and not to give any antipyretic drugs with this therapy, as we consider fever to be one of the positive “side effects” . This means that the patients are closely monitored with regard to their entire physiological functions on a BioMonitor and the fever that sets in is closely monitored. The team of therapists controls the administration of the IL-2 so that maximum temperatures of 39-40 ° are achieved. The treatment time is therefore between 6 and 8 hours, depending on the rate at which the fever increases.
During this time the temperature is measured rectally, the oxygen saturation, the EKG and the blood pressure are constantly monitored and the IL-2 together with taurolidine is carefully infused via perfusors according to the desired fever reaction.
The possible side effects during this therapy are the (desirable) fever, slight headache and nausea, especially on the first day, sometimes a slight rash, sometimes slight diarrhea.
We can confirm the safety and tolerability of IL-2 in combination with Taurolidine. Before being approved for low-dose interleukin 2 therapy, a detailed internal assessment including cardiac echocardiography, exercise ergometry and a large laboratory analysis is required.
🎬 The Unbelievable Plight of Mrs. Wright (2019)
It is an honor for us to be part of this success story. It is difficult for us to put into words the mileage that has been set here. The therapy mentioned above contributed to this. Thanks to Grow Vision and our dear Dr. Diana Wright
BOOK A SKYPE INTERVIEW WITH DR. KLEEF
If the journey to our ordination is too difficult, we offer the option of having the initial consultation via Skype. In the first meeting, the therapy plan is determined, all findings are discussed and the anamnesis is taken. This means that you have all the information you need for the next steps in therapy and you can decide in peace.